Precigen Inc. (NASDAQ:PGEN) is one of the hot stocks to buy with huge upside potential. On October 13, Precigen announced long-term follow-up data for PAPZIMEOS (zopapogene imadenovec-drba), which is an immunotherapy for the treatment of adults with recurrent respiratory papillomatosis/RRP. PAPZIMEOS received full approval from the US FDA in August this year, becoming the first and only approved therapy for adult RRP.
The FDA approval was supported by results from a pivotal study, which demonstrated that 51% of the 35 study patients achieved a complete response, defined as requiring no surgeries in the 12 months following treatment with PAPZIMEOS.
PAPZIMEOS (zopapogene imadenovec-drba) is the first and only approved therapy that addresses the root cause of RRP. It is a non-replicating adenoviral vector-based immunotherapy developed using Precigen’s proprietary AdenoVerse therapeutic platform. The drug is designed to express a fusion antigen composed of selected regions of human papillomavirus/HPV types 6 and 11 proteins, which are the causative agents of RRP, to generate an immune response against them.
Precigen Inc. (NASDAQ:PGEN) is a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
While we acknowledge the potential of PGEN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PGEN and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
Hedge Fund Resource Center